Introduction Daytime sleepiness, reported in about 50% of patients with Parkinson disease (PD), is associated with high morbidity, poor quality of life and increased risk for accidents. While an association between dysautonomia and daytime sleepiness in early, de-novo PD has been reported, our understanding of the role of medications, cognitive status and disease duration on this relationship is inadequate. Methods Data were analyzed from the prospective Cincinnati Cohort Biomarkers Program. The primary outcome of interest was daytime sleepiness, as measured by the Epworth Sleepiness Scale (ESS). The primary exposure variable was orthostatic hypotension (OH) with a sub-analysis for the neurogenic OH (nOH) subtype. Regression analyses were carried out adjusting for the following covariates: age, sex, disease duration, education, comorbidities, anti-cholinergic burden, levodopa equivalent dose (LEDD), motor subscore of the Movement disorder society-unified Parkinson disease rating scale, Hoehn and Yahr stage (H&Y), Beck Depression Inventory, and Beck Anxiety Inventory. Results Data on 456 subjects with PD were analyzed. OH was strongly associated with ESS scores, particularly in those with anticholinergic medication use after adjusting for all covariates (RC, 4.30; p<0.001). This adjusted association was more pronounced in men with early disease duration, early H&Y stage, no cognitive decline, and LEDD≤750 mg. Similar results were noted with nOH. Conclusions OH is associated with daytime sleepiness to a greater extent in male patients with early disease and magnified by such prescribing practices as anticholinergic medication use and dopaminergic dosage in early PD. This relationship is independent of cognitive decline.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was approved by the University of Cincinnati Institutional Review Board

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors